Usana Health Sciences (USNA) Cash from Financing Activities (2011 - 2026)

Usana Health Sciences (USNA) has reported Cash from Financing Activities for 16 consecutive years, with -$3.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 74.83% year-over-year to -$3.6 million; the TTM figure through Apr 2026 stood at -$29.8 million (down 523.45% YoY), while the FY2026 annual figure was -$40.6 million, down 525.03% from the prior year.
• Cash from Financing Activities declined to -$3.6 million in Q2 2026 per USNA's latest filing, from $13.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $22.9 million in Q4 2024 and bottomed at -$122.4 million in Q1 2022.
• Historically, Cash from Financing Activities has averaged -$11.2 million across 5 years, with a median of -$2.3 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 26356.82% — and 2024, when it jumped 3384.8%.
• Usana Health Sciences' Cash from Financing Activities stood at -$150000.0 in 2022, then jumped by 538.67% to $658000.0 in 2023, then surged by 3384.8% to $22.9 million in 2024, then slumped by 104.27% to -$979000.0 in 2025, then tumbled by 271.91% to -$3.6 million in 2026.
• Business Quant data shows USNA's Cash from Financing Activities at -$3.6 million in Q2 2026, $13.5 million in Q1 2026, and -$979000.0 in Q3 2025.